HGS2 cell line

Human tumours comprise a complex mixture of malignant cells, immune, and other stromal cells regulated by a dynamic network of soluble mediators and adhesion molecules. All of these components interact in an abnormal extracellular matrix (ECM), often referred to as the tumor matrisome (Socovich and Naba, 2018). Not only is this tumor microenvironment (TME) critical […]

Contributors

Inventor Institute
Frances Balkwill Queen Mary University of London
Cat. #: 160538
Unit size: 1×10^6 cells / vial
Cancer types: Ovarian cancer
Research Fields: Cancer
Organism: Mouse
Tissue: fallopian tube, ovarian, or peritoneal tumour tissues
Model: Cancer Model
Cancer Types In Detail: High Grade Serous Epithelial Ovarian;High-Grade Serous Ovarian (HGSOC)
Alternate name: ovarian cancer, tumour microenvironment, matrisome, serous, mouse model
Product description: Human tumors comprise a complex mixture of malignant cells, immune, and other stromal cells regulated by a dynamic network of soluble mediators and adhesion molecules. All of these components interact in an abnormal extracellular matrix (ECM), often referred to as the tumor matrisome (Socovich and Naba, 2018). Not only is this tumor microenvironment (TME) critical for the growth and spread of human cancers but also the non-malignant components are important targets for immunological and other biological therapies (Binnewies et al., 2018, Foster et al., 2018, Mantovani et al., 2017). However, it is not clear whether TMEs of murine cancer models sufficiently replicate their human counterparts. Differences between the human and mouse TMEs may compromise pre-clinical studies of novel immune and other biological therapies and their successful translation to clinical trials. Many murine cancer models may not have appropriate oncogenic mutations and may be grown in immunocompromised animals or in unsuitable anatomical sites; others grow too rapidly for a TME to develop fully or too slowly for pre-clinical studies to be feasible. It has been demonstrated that many of the biomechanical, cellular, and molecular features of human HGSOC are replicated in these murine tumors with significant correlations in mRNA expression profiles, innate and adaptive immune responses, tissue modulus, and matrisome components (Maniati et al 2020). Further highlighting the utility of these models as avatars of human disease, the mouse models exhibit significant differences and distinct vulnerabilities in their TMEs, reflecting the heterogeneity of human HGSOC biopsies. Using this model platform, proof-of-concept studies were conducted demonstrating the potential of this repertoire of models for pre-clinical studies and found that the transcriptional profile of chemotherapy-responsive murine tumors translates to patients, suggesting that these mouse models could help identify sub-groups of patients who would most benefit from a specific treatment (Maniati et al 2020).
Conditional: Yes
Production details: The HGS2 cell line was established from dissociated fragments of the fallopian tubes and ovaries from a Pax8-rtTA; TetO-Cre; Trp53fl/fl; Ptenfl/fl; Brca2fl/fl mouse. Individual tumours were collected in cold PBS, minced with a scalpel, and incubated with 1 mg/ml collagenase type I (Fisher, 17018-029). After being split once onto collagen-coated plates, cells were transferred into Primaria flasks (Corning) and then propagated as polyclonal lines on normal cell-culture plastic (Corning). Complete medium was DMEM:F12 1:1 with GlutaMax (GIBCO) with the addition of 4% FBS (Hyclone), 1x Pen/Strep (Invitrogen), 1x insulin/transferrin/selenium (Invitrogen, 51300), 100 ng/ml hydrocortisone (Sigma, H0135), 20 ng/ml murine Epidermal Growth Factor (EGF, Sigma, E4127), 1x antibiotic-antimycotic (GIBCO). Cells were trypsinized with 0.05% trypsin-EDTA (GIBCO). 60577 and 30200 cell lines were derived and cultured as described (Szabova et al., 2014).Orthotopic tumor growth: Cell lines were trypsinized, washed in medium, and resuspended in PBS to 10×106 cells in 300 μl injected i.p. into 8-week old FVB mice (60577, 30200) or 6-7-week old C57BL/6J mice (HGS1-4) from Charles River, UK. Mice were treated with 2 mg/kg anti-IL-6 or isotype control (BioXCell) twice weekly i.p., starting three weeks (60577 model), ten weeks (30200 model) or seven weeks (HGS2 model) after cell injection, until the end of the experiment. Carboplatin (20 mg/kg) was administered i.p. once a week for three weeks starting at week 3 (60577 model), or week 8 (HGS2 model).
Disease: Cancer;Ovarian cancer;High Grade Serous Epithelial Ovarian cancer
Format: Frozen
Storage conditions: Liquid Nitrogen
Shipping conditions: Dry ice
Growth medium: DMEM:F12 1:1 with GlutaMax (GIBCO) with the addition of 4% FBS (Hyclone), 1x Pen/Strep (Invitrogen), 1x insulin/transferrin/selenium (Invitrogen, 51300), 100 ng/ml hydrocortisone (Sigma, H0135), 20 ng/ml murine Epidermal Growth Factor (EGF, Sigma, E4127), 1x antibiotic-antimycotic (GIBCO).
Mycoplasma free: Yes
Biosafety level: 1
References:

Maniati et al. 2020. Cell Rep. 30(2):525-540.e7. PMID: 31940494.

Images

View Gallery
Figure 1. Characterization of Murine HGSOC Models (A) Overview of murine models and the analyses conducted. (B) Left panel

Citations And Reviews

Related Tools for Cell lines

Cat. # Tool Name
151629 MEF Raf1 FF/FF KI Cell Line Key Info View Tool
151014 MCF7 AREc32 Cell Line Key Info View Tool
151446 FLYRD18 Cell Line Key Info View Tool
151449 JIM1 Cell Line Key Info View Tool
151558 MEF Trex1 KO Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.